DUBLIN--(BUSINESS WIRE)--The "Human Chorionic Gonadotropin Market by Technology, Therapeutic Area, and End User - Global Opportunity Analysis and Industry Forecast, 2017-2025" report has been added to ResearchAndMarkets.com's offering.
The global human chorionic gonadotropin (hCG) market generated revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.
Rise in incidence of infertility-related problems in both the genders drive the growth of the global hCG market. In addition, upsurge in the adoption of hCG hormone in pain management and weight loss propel the market growth.
Furthermore, incorporation of recombinant technology for the development of hCG is anticipated to offer lucrative opportunities for the market growth in the near future.
Based on technology, the recombinant technology segment is expected to register the highest growth rate during the forecast period. Based on the therapeutic area, male hypogonadism segment is anticipated to witness the highest growth rate.
Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to its high population base, surge in disposable income, and rise in awareness toward infertility treatment procedures. In addition, rise in fertility tourism in Asia-Pacific countries such as Thailand and Malaysia boosts the market growth.
Select Findings
- The oligospermic treatment segment registered the second highest CAGR during the forecast period among the therapeutic area.
- The fertility clinics end user segment dominated the market, accounting for half of the total share in 2017.
- North America dominated the market, accounting for maximum share of the overall market in 2017.
Key Players
- Bristol Myers Squibb Company
- Merck & Co.
- Ferring
- Fresenius Kabi
- Cigna
- Sun Pharmaceutical Industries
- Lee BioSolutions
- Sanzyme
- Scripps Laboratories
- Lupin
Other Players
- Kamiya Biomedical Company
- Intas Pharmaceuticals
- Prospec-Tany Technogene
- Cipla Limited
- Biocare Medical
- MyBioSource
- Zydus Cadila
- Life Medicare & Biotech
Topics Covered
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Human Chorionic Gonadotropin (HCG) Market, by Technology
Chapter 5: Human Chorionic Gonadotropin (HCG) Market, by Therapeutic Area
Chapter 6: Human Chorionic Gonadotropin (HCG) Market, by End-user
Chapter 7: Human Chorionic Gonadotropin (HCG) Market, by Region
Chapter 8: Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/7gxjcv/worldwide_human?w=4
